Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof
AssigneeEligo Bioscience
InventorsAntoine Decrulle, Xavier Duportet, Igor Stzepourginski
Life of this patent
Estimating the term…
Abstract
The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.
Claims17
A pharmaceutical composition comprising at least two different bacterial delivery vehicles into which the same payload is packaged, wherein the payload comprises:
- a nucleic acid sequence of interest encoding a therapeutic molecule of interest, under the control of a promoter;
- and at least two orthogonal bacterial virus packaging sites that allow packaging of said payload into said at least two different bacterial delivery vehicles and a pharmaceutical acceptable carrier,
- wherein the nucleic acid sequence of interest encodes one or more components of a Cas9 system for the reduction of gene expression or inactivation of a gene, wherein said gene is selected from the group consisting of an antibiotic resistance gene, a virulence factor or virulence protein gene, a toxin factor or toxin protein gene, a bacterial receptor gene, a membrane protein gene, a structural protein gene, a secreted protein gene, and a drug resistance gene, or any combination thereof.
A pharmaceutical composition comprising at least two different bacterial delivery vehicles into which the same payload is packaged, wherein the payload comprises:
- a nucleic acid sequence of interest encoding a therapeutic molecule of interest, under the control of a promoter;
- and at least two orthogonal bacterial virus packaging sites that allow packaging of said payload into said at least two different bacterial delivery vehicles and a pharmaceutical acceptable carrier,
- wherein the at least two orthogonal bacterial virus packaging sites comprise:
- (i) a λ cos site and P4 cos site;
- (ii) a λ cos site, P4 cos site and P1 pac site;
- (iii) a λ cos site, P4 cos site and T7 concatemer junction;
- or (iv) a λ cos site, P4 cos site, P1 pac site and T7 concatemer junction;
- and
- wherein the nucleic acid sequence of interest is selected from the group consisting of a nucleic acid sequence encoding a kinase, a nuclease, a Cas nuclease, a Cas9 nuclease, a guide RNA, a CRISPR locus, a toxin, a TALEN, a ZFN, a meganuclease, a recombinase, a bacterial receptor, a membrane protein, a structural protein, a secreted protein, a gene product conferring resistance to an antibiotic or to a drug, a toxic protein or a toxic factor, a virulence protein and a virulence factor, or any combination thereof.
Dependencies are inferred from the claim text.